# Apatinib With Albumin-bound Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer

> **NCT03942068** · PHASE2 · UNKNOWN · sponsor: **Henan Cancer Hospital** · enrollment: 35 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** albumin-bound paclitaxel
- **DRUG:** Apatinib

## Key facts

- **NCT ID:** NCT03942068
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-09-01
- **Primary completion:** 2020-09-01
- **Final completion:** 2020-12-30
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2019-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03942068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03942068, "Apatinib With Albumin-bound Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03942068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*